Chemoinformaics analysis of Indolo[2,1-b]quinazoline-6,12-dione
| Molecular Weight | 248.241 | nRot | 0 |
| Heavy Atom Molecular Weight | 240.177 | nRig | 8 |
| Exact Molecular Weight | 248.059 | nRing | 4 |
| Solubility: LogS | -3.617 | nHRing | 2 |
| Solubility: LogP | 3.446 | No. of Aliphatic Rings | 1 |
| Acid Count | 0 | No. of Aromatic Rings | 3 |
| Base Count | 0 | No. of Aliphatic Carbocycles Rings | 0 |
| Atoms Count | 27 | No. of Aliphatic Hetero Cycles | 1 |
| No. of Heavy Atom | 19 | No. of Aromatic Carbocycles | 2 |
| nHetero | 4 | No. of Aromatic Hetero Cycles | 1 |
| nBridge Head | 0 | No. Saturated Carbocycles | 0 |
| No. of Hydrogen atom | 8 | No. of Saturated Hetero Cycles | 0 |
| No. of Carbon atom | 15 | No. of Saturated Rings | 0 |
| No. of Nitrogen atom | 2 | No. of Arom Atom | 16 |
| No. of Oxygen atom | 2 | No. of Arom Bond | 17 |
| nHA | 4 | APOL | 34.1883 |
| nHD | 0 | BPOL | 12.6117 |
| QED | 0.477 |
| Synth | 2.258 |
| Natural Product Likeliness | -0.015 |
| NR-PPAR-gamma | 0.174 |
| Lipinski | Accepted |
| Pfizer | Rejected |
| GSK | Accepted |
| Golden Triangle | Accepted |
| Pgp-inh | 0.186 |
| Pgp-sub | 0 |
| HIA | 0.003 |
| CACO-2 | -4.238 |
| MDCK | 0.0000399 |
| BBB | 0.903 |
| PPB | 0.914123 |
| VDSS | 1.971 |
| FU | 0.104477 |
| CYP1A2-inh | 0.991 |
| CYP1A2-sub | 0.577 |
| CYP2c19-inh | 0.965 |
| CYP2c19-sub | 0.09 |
| CYP2c9-inh | 0.93 |
| CYP2c9-sub | 0.278 |
| CYP2d6-inh | 0.407 |
| CYP2d6-sub | 0.118 |
| CYP3a4-inh | 0.391 |
| CYP3a4-sub | 0.25 |
| CL | 3.105 |
| T12 | 0.749 |
| hERG | 0.069 |
| Ames | 0.523 |
| ROA | 0.205 |
| SkinSen | 0.964 |
| Carcinogencity | 0.343 |
| EI | 0.981 |
| Respiratory | 0.96 |
| NR-Aromatase | 0.035 |
| Antiviral | Yes |
| Prediction | 0.726399 |